Niche Focus Greene Street specializes in transdermal pharmaceutical products, presenting a core value proposition for licensing partnerships and co-development opportunities in a niche that reduces GI side effects and aids patients with swallowing difficulties.

Clinical Pipeline Transdermal Innovative Products (TiPs) are advancing toward animal studies and human trials, indicating a tangible near-term licensing opportunity for partners seeking early-access dermatological or systemic delivery platforms.

Control & Manufacturing By combining development and direct manufacture, the company offers end-to-end feasibility for potential collaborators and sponsors, enabling faster time-to-market and streamlined due diligence for co-development deals.

Financial Footing With a revenue range of 1M–10M and a lean employee base, there is opportunity to position targeted, high-ROI partnerships and milestone-driven collaborations that maximize scarce capital for a small biotech-focused sales motion.

Technology & Compliance Existing tech stack and regulatory alignment with FDA guidelines provide a credible foundation for partner studies, clinical data generation, and scalable platform licensing across biopharma channels.